Sigyn Therapeutics, Inc.
SIGY
$4.15
$0.153.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 383.90K | 602.30K | 362.40K | 397.40K | 501.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 478.00K | 808.50K | 602.80K | 630.00K | 717.20K |
| Operating Income | -478.00K | -808.50K | -602.80K | -630.00K | -717.20K |
| Income Before Tax | -522.80K | -1.20M | -862.40K | -758.10K | -1.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -522.80K | -1.20M | -862.40K | -758.10K | -1.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -522.80K | -1.20M | -862.40K | -758.10K | -1.18M |
| EBIT | -478.00K | -808.50K | -602.80K | -630.00K | -717.20K |
| EBITDA | -476.60K | -807.10K | -601.40K | -628.40K | -713.50K |
| EPS Basic | -0.33 | -0.94 | -0.70 | -0.62 | -0.94 |
| Normalized Basic EPS | -0.22 | -0.59 | -0.44 | -0.39 | -0.77 |
| EPS Diluted | -0.33 | -0.94 | -0.70 | -0.62 | -0.94 |
| Normalized Diluted EPS | -0.22 | -0.59 | -0.44 | -0.39 | -0.77 |
| Average Basic Shares Outstanding | 1.59M | 1.27M | 1.24M | 1.23M | 1.25M |
| Average Diluted Shares Outstanding | 1.59M | 1.27M | 1.24M | 1.23M | 1.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |